Skip to main content

Table 1 Clinicopathologic characteristics of all patients

From: Impact of hemodynamic instability during cytoreductive surgery on survival in high-grade serous ovarian carcinoma

Characteristics

All

(n = 338, %)

At the time of diagnosis

 FIGO stage

  IC

19 (5.6)

  II

29 (8.6)

  III

169 (50.0)

  IV

121 (35.8)

 Initial serum CA-125 a, IU/ml

  Median (IQR)

878.0 (289.0–2433.0)

 Primary treatment strategy

  Primary debulking surgery

225 (66.6)

  Neoadjuvant chemotherapy

113 (33.4)

At the time of surgery

 Age, years

  Mean ± SD

57.8 ± 11.2

 BMI, kg/m2

  Median (IQR)

23.2 (20.9–25.4)

  Underweight (<18.5)

24 (7.1)

  Normal (18.5–22.9)

134 (39.6)

  Overweight (23.0–24.9)

81 (24.0)

  Obesity (≥25.0)

99 (29.3)

 Comorbidities

  Hypertension

58 (17.2)

  Diabetes

19 (5.6)

  Liver disease

7 (2.1)

  Heart disease

9 (2.7)

  Renal disease

2 (0.6)

  Vascular disease

2 (0.6)

  Neurologic disease

5 (1.5)

  Asthma

2 (0.6)

 ASA classification

  1

65 (19.2)

  2

220 (65.1)

  3

52 (15.4)

  4

1 (0.3)

 Surgical complexity score

  Median (IQR)

6 (4–9)

  Low (≤3)

33 (9.8)

  Intermediate (4–7)

175 (51.8)

  High (≥8)

130 (38.5)

 Residual tumor after PDS/IDS

  Complete cytoreduction (R0)

253 (74.9)

   < 1 cm

48 (14.2)

  1–2 cm

22 (6.5)

   ≥ 2 cm

15 (4.4)

  1. Abbreviations: ASA American Society of Anesthesiologists, BMI Body mass index, CA-125 Cancer antigen 125, FIGO International Federation of Gynecology and Obstetrics, IDS Interval debulking surgery, IQR Interquartile range, SD Standard deviation
  2. Missing data: a 3